Aardvark Therapeutics (AARD) Assets (2024 - 2026)
Aardvark Therapeutics (AARD) posted Assets of $98.6 million for Q1 2026, down 15.87% sequentially from $117.2 million in Q4 2025, and down 37.21% YoY from $157.0 million in Q1 2025.
Aardvark Therapeutics (AARD) Assets (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Assets for 3 years, with the latest figure at $98.6 million in Q1 2026.
- Quarterly Assets fell 37.21% year-over-year to $98.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.6 million (down 37.21% YoY) and the FY2025 annual result came in at $117.2 million, up 51.19% from the prior year.
- Assets eased to $98.6 million in Q1 2026 per AARD's latest filing, from $117.2 million in the prior quarter.
- Over five years, Assets peaked at $157.0 million in Q1 2025 and troughed at $77.5 million in Q4 2024.
- A 3-year average of $121.8 million and a median of $125.2 million in 2025 frame the typical range for Assets.
- The sharpest annual moves came in 2025 and 2026: Assets surged 51.19% in 2025, then tumbled 37.21% in 2026.
- Over 3 years, Assets stood at $77.5 million in 2024, then soared by 51.19% to $117.2 million in 2025, then declined by 15.87% to $98.6 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $98.6 million, $117.2 million, and $133.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Aardvark Therapeutics | 127.36 Mn | 53.44 Mn | - | 81.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.46 Mn |
| Mar 31, 2026 | 98.59 Mn |
| Dec 31, 2025 | 117.18 Mn |
| Sep 30, 2025 | 133.23 Mn |
| Jun 30, 2025 | 147.48 Mn |
| Mar 31, 2025 | 157.03 Mn |
| Dec 31, 2024 | 77.51 Mn |